TirzepatideUp to 15mg weeklyGLP-1 + GIP~21% avg loss

Mounjaro reviews: what patients report

Mounjaro (tirzepatide) is the newest major weight loss medication in Australia. Patient experiences are still emerging, but early reports are overwhelmingly positive — with some caveats.

What patients commonly report

Positives

  • Dramatic appetite reduction: Many patients describe Mounjaro's appetite suppression as stronger than semaglutide (Wegovy/Ozempic). The dual GLP-1/GIP mechanism appears to produce more profound changes in hunger signalling. Patients commonly report "forgetting to eat" — a novel experience for people who have spent years thinking about food constantly.
  • Faster weight loss: Patients who switched from semaglutide frequently report accelerated weight loss on Mounjaro. Clinical trials support this — ~21% average vs ~15-17% for Wegovy.
  • Reduced cravings: Beyond just appetite, many report reduced cravings for specific foods — particularly sweet and fatty foods. Some describe losing interest in alcohol as well.
  • Improved blood sugar: Particularly noted by patients with type 2 diabetes or pre-diabetes. Mounjaro's GIP pathway has additional glucose-lowering effects.
  • Energy improvement: As weight comes off and blood sugar stabilises, many report feeling more energetic and sleeping better.

Common complaints

  • GI side effects during escalation: Nausea, diarrhoea, and constipation are common in the first 4–8 weeks at each dose increase. Most patients report these improving within 1–2 weeks at each level.
  • Cost: At $350–500/month with no PBS prospect, cost is the primary barrier. Many patients express frustration that such an effective medication is unaffordable for long-term use.
  • Appetite can be too suppressed: Some patients report needing to force themselves to eat enough to maintain nutrition. This can lead to fatigue and nutrient deficiency if not managed.
  • Injection site reactions: More commonly reported with Mounjaro than semaglutide — redness, itching, or small lumps at the injection site.
  • Longer escalation: 20 weeks to reach maximum dose vs 16 for Wegovy means a longer ramp-up period.

Tips from experienced users

  • Prioritise protein at every meal — when eating less, what you eat matters more
  • Rotate injection sites to minimise skin reactions
  • Stay hydrated — dehydration worsens every side effect
  • Don't rush the escalation — staying at a lower dose longer can be more comfortable and still effective
  • Track non-scale victories: measurements, energy levels, sleep quality, blood test results

Note: These observations are compiled from publicly available reviews on Australian forums, social media, and published patient-reported outcome data. Individual experiences vary significantly.

← Back to Mounjaro guide

Ask our AI advisor